# Sanofi (SNY)

Source: https://www.quantisnow.com/company/SNY
Generated: 2026-11-22T22:03:05.127Z

- Ticker: SNY
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001121404
- Website: sanofi.com

## About

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

## Latest SNY news and filings

- 2026-11-19 11:26 UTC [FDA Approval for INFILBRAY issued to GENZYME CORP A SANOFI CO](https://www.quantisnow.com/insight/fda-approval-for-infilbray-issued-to-genzyme-corp-a-sanofi-6799726)
- 2026-11-16 14:15 UTC [Sanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patients](https://www.quantisnow.com/insight/sanofi-and-the-pan-canadian-pharmaceutical-alliance-sign-letter-of-intent-6792821)
- 2026-11-12 14:21 UTC [FDA Approval for CHILDREN&#39;S ALLEGRA HIVES issued to CHATTEM SANOFI](https://www.quantisnow.com/insight/fda-approval-for-children39s-allegra-hives-issued-to-chattem-sanofi-6786938)
- 2026-11-12 14:21 UTC [FDA Approval for RIFADIN issued to SANOFI AVENTIS US](https://www.quantisnow.com/insight/fda-approval-for-rifadin-issued-to-sanofi-aventis-us-6786937)
- 2026-11-12 14:21 UTC [FDA Approval for CHILDREN&#39;S ALLEGRA ALLERGY issued to CHATTEM SANOFI](https://www.quantisnow.com/insight/fda-approval-for-children39s-allegra-allergy-issued-to-chattem-sanofi-6786935)
- 2026-11-12 14:21 UTC [FDA Approval for ALLEGRA ALLERGY issued to CHATTEM SANOFI](https://www.quantisnow.com/insight/fda-approval-for-allegra-allergy-issued-to-chattem-sanofi-6786933)
- 2026-11-12 14:21 UTC [FDA Approval for ALLEGRA HIVES issued to CHATTEM SANOFI](https://www.quantisnow.com/insight/fda-approval-for-allegra-hives-issued-to-chattem-sanofi-6786932)
- 2026-11-10 09:48 UTC [FDA Approval for ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION issued to CHATTEM SANOFI](https://www.quantisnow.com/insight/fda-approval-for-allegra-d-24-hour-allergy-and-congestion-issued-6782405)
- 2026-11-09 12:30 UTC [Analyst Upgrade] [Sanofi upgraded by BNP Paribas Exane](https://www.quantisnow.com/insight/sanofi-upgraded-by-bnp-paribas-exane-6780218)
- 2026-11-05 13:35 UTC [SEC Form 13F-HR filed by Sanofi](https://www.quantisnow.com/insight/sec-form-13f-hr-filed-by-sanofi-6775053)
- 2026-10-30 12:49 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6764726)
- 2026-10-29 11:30 UTC [Sanofi expands Canadians' COVID-19 vaccine choice with availability of Nuvaxovid®for the 2026-2027 respiratory season](https://www.quantisnow.com/insight/sanofi-expands-canadians-covid-19-vaccine-choice-with-availability-of-nuvaxovidfor-6762515)
- 2026-10-26 10:41 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6756854)
- 2026-10-20 13:10 UTC [ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics](https://www.quantisnow.com/insight/scionxbio-announces-collaboration-to-develop-long-acting-xrna-therapeutics-6751781)
- 2026-10-15 16:00 UTC [Sanofi and pCPA Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care](https://www.quantisnow.com/insight/sanofi-and-pcpa-sign-letter-of-intent-for-dupixent-across-6747762)
- 2026-10-14 13:45 UTC [AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test](https://www.quantisnow.com/insight/ai-designed-biologics-are-moving-from-the-screen-to-the-bench-6746228)
- 2026-10-09 12:30 UTC [Analyst Coverage Initiated] [Wolfe Research initiated coverage on Sanofi](https://www.quantisnow.com/insight/wolfe-research-initiated-coverage-on-sanofi-6742446)
- 2026-10-02 15:57 UTC [Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®](https://www.quantisnow.com/insight/sanofi-and-2026-nba-champion-karl-anthony-towns-team-up-to-6733891)
- 2026-10-01 16:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6732023)
- 2026-09-17 10:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6718298)
- 2026-09-16 14:30 UTC [Sanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment](https://www.quantisnow.com/insight/sanofi-inaugurates-new-flu-vaccine-facility-canadas-largest-biomanufacturing-investment-6717229)
- 2026-09-10 13:05 UTC [Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™](https://www.quantisnow.com/insight/sanofi-partners-with-usa-pickleball-to-launch-serve-up-protection-6711161)
- 2026-09-09 13:38 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on Sanofi](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-sanofi-6709696)
- 2026-09-08 12:30 UTC [A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach](https://www.quantisnow.com/insight/a-micro-cap-biotech-just-cleared-a-milestone-most-never-reach-6707670)
- 2026-09-08 12:00 UTC [Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®](https://www.quantisnow.com/insight/sanofi-and-keke-palmer-team-up-to-urge-parents-to-6707583)
- 2026-08-25 10:06 UTC [SEC Form N-PX filed by Sanofi](https://www.quantisnow.com/insight/sec-form-n-px-filed-by-sanofi-6693458)
- 2026-08-12 12:18 UTC [SEC Form 4] [Large owner Sanofi converted options into 672,778 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-sanofi-converted-options-into-672778-shares-sec-form-6677145)
- 2026-08-12 12:09 UTC [SEC Form 3] [SEC Form 3 filed by new insider Sanofi](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-sanofi-6677113)
- 2026-08-07 19:45 UTC [Insider Buy] [Large owner Sanofi converted options into 782,855 shares and bought $5,100,000 worth of shares (300,000 units at $17.00) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-sanofi-converted-options-into-782855-shares-and-bought-6671321)
- 2026-08-06 10:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6666842)
- 2026-08-04 21:08 UTC [SEC Form 3] [SEC Form 3 filed by new insider Sanofi](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-sanofi-6663070)
- 2026-07-30 11:34 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6655019)
- 2026-07-30 10:28 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6654688)
- 2026-07-28 10:15 UTC [SEC Form 13F-HR filed by Sanofi](https://www.quantisnow.com/insight/sec-form-13f-hr-filed-by-sanofi-6650446)
- 2026-07-27 10:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6648857)
- 2026-07-27 08:50 UTC [FDA Approval for AVAPRO issued to SANOFI AVENTIS US](https://www.quantisnow.com/insight/fda-approval-for-avapro-issued-to-sanofi-aventis-us-6648789)
- 2026-07-17 10:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6640427)
- 2026-07-13 18:11 UTC [FDA Approval for SARCLISA ESCENA issued to SANOFI-AVENTIS U.S. LLC](https://www.quantisnow.com/insight/fda-approval-for-sarclisa-escena-issued-to-sanofi-aventis-us-llc-6635207)
- 2026-07-07 13:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-sanofi-6629737)
- 2026-06-30 17:27 UTC [SEC Form 11-K] [SEC Form 11-K filed by Sanofi](https://www.quantisnow.com/insight/sec-form-11-k-filed-by-sanofi-6620520)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SNY
- Earnings history: https://www.quantisnow.com/earnings/SNY
- Dividend history: https://www.quantisnow.com/dividends/SNY
- Insider transactions: https://www.quantisnow.com/insiders/SNY
- Options chain: https://www.quantisnow.com/options/SNY
- SEC 8-K filings only: https://www.quantisnow.com/company/SNY/8-k
- RSS and alerts for SNY: https://www.quantisnow.com/docs/rss-feeds.md
